As pharmaceutical marketers prepare for brand planning for 2027, the rise of artificial intelligence (AI) necessitates a strategic shift in budget allocation—specifically towards developing a share of answer (SOA) strategy. This new focus challenges traditional metrics that prioritize share of voice and omnichannel presence, especially in light of the fact that 81% of U.S. physicians are now utilizing AI tools in their clinical practice. Marketers need to evolve from merely being visible to being referenced.
The Shift in Healthcare Provider Engagement
Clinicians have become savvy consumers of technology, increasingly turning to large language models (LLMs) like ChatGPT and Claude for answers to clinical inquiries. This transition reflects a broader trend in how healthcare providers (HCPs) seek information, making it imperative for pharma marketers to adapt their strategies accordingly.
Recent data illustrates this shift. A significant portion of U.S. physicians reported using AI platforms like OpenEvidence during clinical encounters, with 54% of healthcare professionals worldwide indicating they rely on generative AI for scientific information. Remarkably, many professionals view these AI tools as more crucial than traditional sales representatives for accessing pertinent clinical data.
Adapting Marketing Strategies to AI
In response to the growing reliance on AI, pharma marketers are beginning to rethink their approaches, particularly in optimizing their content for AI-driven search engines. The focus has shifted towards ensuring that their digital assets are compatible with AI crawlers, allowing them to be integrated seamlessly into the information flow. Stephen Onikoro, COO of PharmaForceIQ, emphasizes that while there have been advancements in organic strategies, 2027 will see many pharmaceutical companies allocating substantial portions of their budgets to AI-driven campaigns.
However, the challenge lies in the high costs associated with impressions-based advertising on these platforms, especially when such investments are made without the necessary audience data. Many marketers currently lack the insights needed to accurately assess HCP interactions with AI platforms, which can lead to poor returns on investment if not managed wisely.
The Importance of Data-Driven Decisions
Before committing significant budgets to AI marketing, it is crucial for pharma marketers to obtain reliable data concerning HCP behavior. Affinity data has long been used to guide advertising expenditure but can now be extended to encompass AI platforms. PharmaForceIQ, for instance, utilizes a dynamic system that continuously maps affinity data to HCP behaviors across both consumer LLMs and clinical AI platforms. This approach provides valuable insights into which HCPs are utilizing specific tools, allowing marketers to make informed decisions.
Going further, understanding the motivations behind HCP inquiries is equally vital. By employing agent plug-ins, marketers can gain access to deeper insights that reveal the types of questions HCPs are asking and the context behind those inquiries. This exchange of information can help refine marketing strategies and enhance the relevance of the information being presented.
Navigating the Share of Answer Landscape
For many pharma marketers, the concept of SOA may invoke apprehension due to the rapidly evolving landscape. However, leveraging the right data can clarify decision-making processes and unlock new opportunities for engagement.
Onikoro notes that for years, marketers have focused on building share of voice across various channels. The rise of AI now presents an opportunity for personalized interactions with HCPs, allowing marketers to address specific questions in a more targeted manner. This evolution has the potential to transform how pharmaceutical brands connect with healthcare professionals, fostering deeper relationships and better communication.
The Path Forward
Navigating the complexities of AI-driven marketing requires a thoughtful approach rooted in data. As marketers shift their focus from share of voice to share of answer, they must prioritize understanding their audience’s behaviors and preferences.
- Data is Key: Reliable insights into HCP behaviors are essential for effective budget allocation and campaign planning.
- Embrace AI Tools: Marketers should optimize their content for AI platforms to ensure visibility and relevance in a digital-first landscape.
-
Personalized Engagement: By understanding the specific needs and inquiries of HCPs, marketers can create more meaningful connections.
In conclusion, as the pharmaceutical industry increasingly integrates AI into its marketing strategies, adopting a share of answer approach is crucial. With the right data and insights, marketers can navigate this new terrain, leading to more effective engagement with healthcare providers and ultimately enhancing patient care.
Read more → www.biopharmadive.com